Once-a-day pill falls short.People with HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. have long waited for a once-a-day pill to treat the disease, and it looked like they might finally get it this year. That was until pharmaceutical giant Gilead Sciences Gilead Sciences NASDAQ: GILD is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. announced in August that a second attempt to combine its combination anti-HIV medication Truvada with Bristol-Myers Squibb's Sustiva Sus·ti·va A trademark for the drug efavirenz. efavirenz Sustiva Pharmacologic class: Nonnucleoside reverse transcriptase inhibitor Therapeutic class: Antiretroviral had failed. The latest formulation formulation /for·mu·la·tion/ (for?mu-la´shun) the act or product of formulating. American Law Institute Formulation of the drugs did not achieve the same bioequivalency as individual doses of the medications, Gilead officials said. The two companies are now considering new approaches and hope to file for Food and Drug Administration approval in the first half of 2006. |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion